Defining the Functional and Neuro-Protective Potential of ACTHAR in Acute Optic Neuritis

Completed · Early Phase 1

Conditions studied: Optic Neuritis

In brief

The goal of the study is to determine the earliest structural changes in the optic nerve during the acute event and during the twelve months of recovery following Acthar treatment.

Key facts

Study ID

NCT01987167

Run by

Neuro-Ophthalmologic Associates, PC

People needed

25

Starts

2013-11-01

Expected to finish

2016-12-01

Last updated by the study team

2017-08-22

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: accepted.

You may qualify if…

• unilateral acute demyelinating optic neuritis
• Able to provide informed consent
• age 18 or older
• can perform the above listed electrophysiologic diagnostic testing
• can perform high and low contrast visual acuity and visual field perimetry

You may not qualify if…

• prior diagnosis of remitting/relapsing multiple sclerosis(RRMS)
• secondary progressive MS(SPMS)
• primary progressive MS (PPMS)
• undergoing treatment with medications approve for treatment of RRMS(except corticosteroids for a condition not involving central nervous system demyelination)
• prior diagnosis of systemic lupus erythematosis
• mixed connective tissue disease
• vasculitis
• sarcoidosis
• neuro-myelitis optica

Where it is running

• Neuro Ophthalmology — Philadelphia, Pennsylvania, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.